Selpercatinib and Pseudo-Decreases in Kidney Function

202412 citationsletter

Authors

Hassan Izzedine · Ramsay Santé Hôpital privé des Peupliers

Élise Bouderlique · Hôpital Européen Georges-Pompidou

Benjamin Besse · Institut Gustave Roussy

Abstract

Selpercatinib leads to pseudo-decreased kidney function, which impairs tubular creatinine excretion. Cystatin C has no tubular secretion and may be a better marker for managing selpercatinib treatment.

Topics & Keywords

Renal cell carcinoma treatment PI3K/AKT/mTOR signaling in cancer Cancer Mechanisms and Therapy

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: New England Journal of Medicine

Volume 390, Issue 13, pp. 1241-1243

DOI: 10.1056/nejmc2400216

Field-Weighted Citation Impact: 5.05